menu
    • menu
    [{"orgOrder":0,"company":"Taichung Veterans General Hospital","sponsor":"TSH Biopharm Corporation Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Taichung Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taichung Veterans General Hospital \/ TSH Biopharm Corporation Limited","highestDevelopmentStatusID":"1","companyTruncated":"Taichung Veterans General Hospital \/ TSH Biopharm Corporation Limited"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","sponsor":"Heinrich-Heine University, Duesseldorf","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Heinrich-Heine University, Duesseldorf","highestDevelopmentStatusID":"8","companyTruncated":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Heinrich-Heine University, Duesseldorf"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Eye Institute \/ The Emmes Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"National Eye Institute \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sutter Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sutter Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutter Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sutter Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Foundation Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Brompheniramine Maleate","moa":"||Histamine H1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Foundation Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Foundation Consumer Healthcare"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Promethazine Hydrochloride","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Dextromethorphan Hydrobromide

    Menu

    Dextromethorphan Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Reckitt Benckiser

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mucinex Children's Launches Mighty Chews

                            Details : Mighty Chews consisting, Dextromethorphan HBr, is the first and only over-the-counter medicated children's soft chew for cough relief.

                            Product Name : Mighty Chews

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 30, 2024

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promethazine Hydrochloride,Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Launches Oral Solution For Cough And Allergy Relief

                            Details : Promethazine HCl and Dextromethorphan Hydrobromide-Generic is an approved oral solution, which is indicated for the patients suffering from cough.

                            Product Name : Promethazine HCl-Dextromethorphan HBr-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2024

                            Lead Product(s) : Promethazine Hydrochloride,Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GSK

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brompheniramine Maleate,Dextromethorphan Hydrobromide,Phenylephrine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Foundation Consumer Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Foundation Consumer Healthcare to Add Seven Over-the-Counter Brands to Expanding Portfolio of Healthcare Produ...

                            Details : This diverse portfolio of products includes Breathe Right® Nasal Strips, the world’s #1 nasal strip, and Children’s Dimetapp®, the #1 pharmacist-recommended brand for children's cough and cold products, as well as Anbesol®, Alavert®, Dristan®, P...

                            Product Name : Dimetapp

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 16, 2020

                            Lead Product(s) : Brompheniramine Maleate,Dextromethorphan Hydrobromide,Phenylephrine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Foundation Consumer Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pfizer Inc

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dextromethorphan Pediatric Acute Cough Study

                            Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cough.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 08, 2016

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Otsuka Holdings

                            Japan arrow
                            AAPS
                            Not Confirmed

                            Otsuka Holdings

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar ...

                            Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pseudobulbar Palsy.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 14, 2015

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Taichung Veterans General Hospital

                            Country arrow
                            AAPS
                            Not Confirmed

                            Taichung Veterans General Hospital

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : TSH Biopharm Corporation Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis

                            Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 20, 2015

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : TSH Biopharm Corporation Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sutter Health

                            Country arrow
                            AAPS
                            Not Confirmed

                            Sutter Health

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nuedexta for the Treatment of Adults With Autism

                            Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autistic Disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 28, 2012

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Profil Institut für Stoffwechselforschung GmbH

                            Country arrow
                            AAPS
                            Not Confirmed

                            Profil Institut für Stoffwechselforschung GmbH

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Heinrich-Heine University, Duesseldorf

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects

                            Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 28, 2011

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Heinrich-Heine University, Duesseldorf

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            National Eye Institute

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            National Eye Institute

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : The Emmes Company, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dextromethorphan for Diabetic Macular Edema

                            Details : Dextromethorphan HBr is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 27, 2011

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : The Emmes Company, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth